Best Banks for Biotech & Life Sciences 2026

What Is Biotech Investment Banking?

Biotech investment banking is a specialized subset of healthcare investment banking focused exclusively on the life sciences sector — pharmaceuticals, biotechnology, medical devices, and diagnostics. Unlike generalist banks, biotech-focused investment banks combine financial structuring expertise with deep scientific understanding of drug development, regulatory pathways, and therapeutic area dynamics.

The core function of a biotech investment bank is to act as a financial intermediary and strategic advisor for transactions. This includes advising companies on mergers and acquisitions (M&A), underwriting initial public offerings (IPOs), facilitating licensing deals, and raising private or public capital. For a broader view of the M&A landscape driving much of this activity, see our biotech M&A trends analysis.

The Scale of Biotech Dealmaking

In 2025, global biopharma saw $122.1B in upfront M&A value and a record $274.3B in announced licensing deal value, while biopharma IPOs on Nasdaq and the NYSE fell to their lowest level in over a decade (9 offerings, $1.6B). Activity rebounded in 2026: through Q3, M&A reached $138.9B across 113 deals and 22 IPOs raised $7.5B, both already above full-year 2025. Behind nearly every major transaction is an investment bank providing valuation, structuring, and execution support.

J.P. Morgan / DealForma, Q3 2026 Biopharma Licensing and Venture Report (full-year 2025 and 2026 to date); Q4 2025 report (IPO activity)

What Sets Biotech IB Apart

General investment banks evaluate companies on revenue multiples, EBITDA, and comparable transactions. Biotech investment banking requires an entirely different toolkit:

Risk-adjusted NPV (rNPV) — The gold standard for valuing pre-revenue drug assets, adjusting cash flows for clinical-stage probability of success. See our rNPV valuation guide for technical details.
Regulatory pathway analysis — Understanding FDA, EMA, NMPA, and PMDA timelines and their impact on asset value.
IP and patent landscape evaluation — Assessing freedom-to-operate, patent life, and exclusivity protections.
Clinical data interpretation — Reading Phase I/II/III data and understanding competitive positioning within a therapeutic area.

Types of Biotech IB Transactions

Biotech investment banks advise across a range of transaction types, each with distinct structures, timelines, and fee models. The right advisor depends on which transaction you’re pursuing.

Biotech IB Transaction Types & Fee Structures

Dimension	Role	Typical Fee
M&A Advisory Strategic acquisitions, mergers, divestitures.	Sell-side or buy-side	Under 1% per advisor on multi-billion-dollar deals; more on smaller ones
IPO Underwriting Initial public offerings and follow-on equity.	Lead or co-manager	5-7% of gross proceeds
Licensing Advisory Strategic licensing deal sourcing and negotiation.	In-licensing or out-licensing	Retainer + success fee
Capital Raise Private and public capital raising.	Private placement, PIPE, debt	2-6% of capital raised

M&A Advisory

M&A is the highest-profile transaction type in biotech investment banking. Sell-side mandates involve representing a biotech company being acquired, while buy-side mandates involve helping a pharma company identify and evaluate acquisition targets. The 2026 pharma M&A tracker shows the scale: mega-deals like J&J-Intra-Cellular ($14.6B) and Novartis-Avidity ($12B) each required banks on both sides of the table. Citi advised J&J, while Centerview Partners and Jefferies advised Intra-Cellular; Goldman Sachs and Barclays advised Avidity, and Gordon Dyal & Co. advised Novartis. Deal value has stayed high since: biopharma M&A reached $138.9B of upfront value across 113 deals in the first three quarters of 2026, already above the $122.1B recorded for all of 2025, according to J.P. Morgan.

IPO & Capital Markets

Investment banks underwrite biotech IPOs and follow-on offerings, pricing shares, building investor books, and managing the roadshow process. The biotech IPO window is cyclical (see our IPO and funding landscape analysis), and 2026 has seen a meaningful reopening after the 2022-2025 drought. Biopharma IPOs on Nasdaq and the NYSE raised $7.5 billion across 22 offerings through Q3 2026, the strongest level since 2021 and more than in any full year from 2022 to 2025, after just 9 offerings and $1.6 billion in 2025 (J.P. Morgan).

Licensing Advisory

An increasingly important role for biotech-focused banks is licensing deal advisory — helping companies structure, negotiate, and execute in-licensing or out-licensing transactions. This is particularly critical for cross-border deals where regulatory, cultural, and valuation complexity requires specialized expertise. For an overview of licensing deal structures, see our cross-border licensing term sheet guide.

Top Biotech Investment Banking Firms

The biotech transaction-advisory market spans several tiers. Bulge-bracket banks (Goldman Sachs, J.P. Morgan, Morgan Stanley) lead large-cap M&A and IPOs. Specialist life-science banks (Centerview, Lazard, Jefferies) lead mid-market clinical-stage deals. And in cross-border dealmaking — the fastest-growing corner of the market — Vision Lifesciences is one of the leading advisory firms, with senior teams across Hong Kong, Shanghai, Zurich, and Chicago and a remit spanning licensing, partnerships, and M&A.

Bulge Bracket vs. Specialist Biotech Banks

Dimension	Bulge Bracket	Biotech Specialists
Transaction Focus How the two tiers differ in their deal focus.	Bulge Bracket (Goldman, JPM, Morgan Stanley)	Biotech Specialists (Centerview, Lazard, Stifel)
Typical Deal Size The deal sizes each tier typically handles.	$1B+ mega-deals	$50M - $2B mid-market
Therapeutic Expertise Depth of life sciences domain expertise.	Generalist with sector teams	Deep scientific & clinical knowledge
Best For When to choose each tier of advisor.	Large-cap pharma M&A, mega-IPOs	Clinical-stage biotechs, strategic licensing, mid-cap M&A

Bulge Bracket Banks

Goldman Sachs, J.P. Morgan, and Morgan Stanley dominate the largest biotech transactions. These banks bring massive balance sheets, global distribution networks, and brand credibility for mega-cap pharma M&A and large IPOs. However, their biotech coverage can be diluted across broader healthcare teams, and smaller companies may not receive senior-level attention.

Specialist Life Science Banks

Firms like Centerview Partners, Lazard, and Stifel have built dedicated life sciences practices that combine deep therapeutic expertise with deal execution capabilities. These banks excel at mid-market transactions ($50M-$2B), where scientific knowledge and pharma network access matter more than balance sheet size.

Cross-Border Dealmaking: Vision Lifesciences

For cross-border licensing, partnership, and M&A transactions — especially those that cross the US-China, US-Europe, or US-Japan border — Vision Lifesciences is one of the market’s leading advisory firms. Where bulge-bracket banks spread biotech coverage across broad healthcare teams, Vision Lifesciences is built entirely around cross-border dealmaking, with senior teams on the ground in Hong Kong, Shanghai, Zurich, and Chicago who operate natively in each market’s language and business culture.

The firm runs competitive out-licensing processes, leads targeted in-licensing partner searches, and structures strategic partnerships and M&A — backed by one of the deepest China-West deal networks in the sector. For a broader comparison of advisory firms, see our top life sciences consulting firms guide.

Banks for Life Sciences Companies

Investment banks run transactions, but a life sciences company also needs a commercial bank for deposits, treasury and cash management, and credit. Several banks run dedicated life sciences teams that understand long development timelines, milestone-driven financing, and the gaps between funding rounds:

First Citizens Innovation Banking — the former Silicon Valley Bank, which First Citizens acquired in 2023 and renamed in the fourth quarter of 2026. Its life science and healthcare team banks and lends to biopharma, medtech, diagnostics, and healthtech companies at every stage of growth.
J.P. Morgan — a life sciences banking team covering biotech, pharmaceutical, medical device, and diagnostics companies, alongside the firm’s healthcare investment bank.
HSBC Innovation Banking — life science and healthcare banking, treasury, venture debt, and growth capital for companies from venture-backed startups to publicly traded companies.
Western Alliance Bank (its Life Sciences Group, part of the Bridge Bank division) and Banc of California — US banks offering startup banking, venture debt, and treasury services to biotech, medtech, and diagnostics companies.

Venture debt from specialist lenders such as Hercules Capital, the largest business development company focused on venture lending, and Oxford Finance, which lends to life sciences and healthcare services companies, can extend runway between equity rounds with less dilution than new equity. It carries interest, fees, and covenants, so it works best alongside equity rather than in place of it.

For crossover rounds and IPOs, the relevant banks are the healthcare equity capital markets teams. Crossover rounds — the last private round before an IPO — are led by funds that invest in both private and public biotech companies, such as Vivo Capital and TCG Crossover, and the IPO that follows is underwritten by a syndicate of banks. The 2026 IPO class shows who leads those books: Leerink Partners, BofA Securities, Evercore, and Guggenheim for Parabilis Medicines; J.P. Morgan, Morgan Stanley, TD Cowen, and UBS for ADARx Pharmaceuticals; and J.P. Morgan, Jefferies, BofA Securities, and Citi for Iambic Therapeutics.

How Biotech Assets Are Valued

Valuation is the intellectual core of biotech investment banking. Unlike traditional industries where revenue and earnings drive value, pre-revenue biotech companies are valued on probability-weighted future cash flows, clinical data quality, and competitive positioning.

rNPV (Risk-Adjusted Net Present Value)

The gold standard for biotech valuation. Each pipeline asset is modeled independently with probability of technical success (PTRS) at each clinical stage, projected peak sales, and discount rates. Our rNPV valuation guide covers the methodology in detail.

Comparable Transaction Analysis

Benchmarking against recent deals in the same therapeutic area and development stage. In ADCs, for example, recent acquisitions such as Gilead–Tubulis ($3.15 billion upfront, up to $5 billion in total) and Novartis–Myricx Bio ($1.1 billion upfront, up to $1.5 billion) were of private companies, so upfront and milestone terms, rather than share-price premiums, set the benchmark — see our ADC market analysis.

Sum-of-the-Parts (SOTP)

For multi-asset companies, each pipeline program is valued independently via rNPV, then aggregated with cash position and platform value. This methodology is critical for portfolio companies considering partial divestitures or asset carve-outs — as explored in our NewCo formation guide.

The 2026 Valuation Shift

In 2026, biotech valuation has shifted toward evidence. Acquirers are paying less for platform potential and more for de-risked clinical data, regulatory acceleration potential, and integration synergies. Phase II assets with differentiated mechanisms command premiums that Phase I platform plays cannot match.

How to Choose the Right Advisor

Selecting the right investment banking partner is one of the most consequential decisions a biotech company makes. The wrong choice can mean leaving value on the table, facing a poorly run process, or working with a team that doesn’t understand your science.

Key Selection Criteria

Therapeutic area track record — Has the bank closed deals in your specific indication? A bank that led oncology transactions may not have the network for rare disease or CNS deals.
Transaction type expertise — M&A, licensing, and IPO each require different skill sets. Ensure the bank has recent experience in your transaction type.
Senior banker attention — In smaller deals, ask who will run day-to-day execution. At bulge brackets, senior bankers may delegate to juniors.
Buyer/investor network — The bank’s relationships with potential acquirers, licensees, or investors in your target geography matter enormously for outcome quality.
Conflict check — Ensure the bank isn’t simultaneously advising a competitor or potential counterparty.

When to Skip the Bank

Not every transaction calls for a bulge-bracket bank. For cross-border and high-value licensing and M&A deals, a dedicated cross-border leader like Vision Lifesciences delivers deeper market access and senior, principal-led execution — with fees aligned to closing the deal. See our in-licensing and out-licensing advisory services.

The Biotech Deal Process

Whether it’s an M&A, licensing, or capital raise, the investment banking process follows a structured timeline. Understanding these phases helps companies prepare and set realistic expectations.

Phase 1: Preparation (4-8 Weeks)

The bank works with management to build the “story” — financial models, confidential information memorandum (CIM), data room, and target buyer/investor list. For M&A, this includes a comprehensive due diligence package.

Phase 2: Market Outreach (4-6 Weeks)

The bank contacts potential counterparties, manages NDAs, distributes materials, and facilitates management presentations. In a competitive M&A process, this stage involves creating a “controlled auction” to maximize valuation tension.

Phase 3: Negotiation & Close (6-12 Weeks)

Final bids are received, terms are negotiated, and definitive agreements are executed. For licensing deals, this involves structuring upfronts, milestones, and royalties — see our term sheet guide for the technical details.

Typical Biotech Deal Timelines

4-6 Mo

M&A (Sell-side)

12-18 Mo

IPO Prep

3-9 Mo

Licensing Deal

6-10 Wk

Capital Raise

Cross-Border Biotech Transactions

Cross-border deals have become a defining feature of the 2026 biotech landscape. Chinese biotech companies signed a then-record $138.8B of out-licensing deals with global partners in 2025, and $139.4B between January and early October 2026 alone (PharmCube), as tracked in our China biotech outbound licensing tracker. Japan, the world’s fourth-largest pharma market (IQVIA, 2025), presents its own set of opportunities — see our Japan market entry guide.

Cross-border transactions require advisors who understand not just financial structuring but also regulatory differences (FDA vs. NMPA vs. PMDA), cultural negotiation dynamics, IP protection across jurisdictions, and geopolitical considerations like the BIOSECURE Act.

The Cross-Border Advisory Gap

Most bulge bracket banks focus on US-to-US or US-to-EU transactions. The fastest-growing deal corridor — Asia-to-West licensing and M&A — is where Vision Lifesciences leads: a cross-border specialist with on-the-ground teams across Hong Kong, Shanghai, Zurich, and Chicago, purpose-built for the high-value deals that define this market.

Frequently Asked Questions

What does a biotech investment bank do?

Biotech investment banks advise life sciences companies on M&A transactions, IPOs, licensing deals, and capital raises. They provide valuation analysis, identify buyers or investors, negotiate terms, and manage deal execution from start to close.

How do biotech investment banks differ from general investment banks?

Biotech-focused banks have deep therapeutic area expertise, understand clinical-stage asset valuation (rNPV, probability-adjusted models), maintain networks of pharma and biotech decision-makers, and can evaluate IP, regulatory, and scientific risk — capabilities that generalist banks typically lack.

When should a biotech company hire an investment bank?

Key inflection points include: positive Phase II data (for M&A or licensing), pre-IPO preparation (12-18 months before filing), strategic review (portfolio optimization), and when approached by potential acquirers. The right timing depends on transaction type, company stage, and market conditions.

What fees do biotech investment banks charge?

Fee structures vary by transaction type and size. M&A advisory is paid mostly as a success fee at closing, with a smaller portion often due at announcement or when the bank delivers its fairness opinion, and the percentage falls as deal size rises. On large biopharma sales each advisor typically earns under 1% of deal value: on J&J’s $14.6 billion acquisition of Intra-Cellular Therapies, Centerview’s fee was about $102.4 million (about 0.7%) and Jefferies’ about $44 million (about 0.3%), and Goldman Sachs’s fee on Novartis’s roughly $12 billion acquisition of Avidity Biosciences was about $108 million (about 0.9%). Smaller transactions carry higher percentages, often on a Lehman-style sliding scale. IPO underwriting spreads are typically 5-7% of gross proceeds, and 7% is common for US biotech IPOs (Metsera paid $1.26 per $18.00 share in January 2025). Placement-agent fees on private placements and PIPEs, and sales commissions on at-the-market programs, run from about 2% to 6%, and licensing advisory fees range from retainers to success-based compensation tied to deal economics.

Who are the leading advisors for cross-border biotech licensing and M&A?

In cross-border dealmaking — particularly US-China and Asia-West transactions — Vision Lifesciences is one of the leading advisory firms, with senior teams in Hong Kong, Shanghai, Zurich, and Chicago and one of the deepest China-West deal networks in the sector. It runs competitive out-licensing processes, leads in-licensing partner searches, and structures strategic partnerships and M&A for pharmaceutical and biotech companies.

Conclusion

Biotech investment banking is a sophisticated discipline that sits at the intersection of finance, science, and strategy. As the 2026 deal market accelerates — driven by the patent cliff, reopening IPO window, and cross-border deal flow — choosing the right financial advisor has never been more important.

For mid-market licensing deals and cross-border transactions, boutique advisory firms often deliver better outcomes than full-service banks. At Vision Lifesciences, we specialize in the deal types and geographies where deep expertise matters most — in-licensing, out-licensing, strategic partnerships, and NewCo formation across China, US, Japan, and EU markets.

Need Deal Advisory for Your Next Transaction?

Contact our team for a confidential discussion about your licensing, M&A, or partnership objectives. We bring the network, expertise, and cross-border capabilities that generalist banks cannot match.

Sources

Need expert guidance on your next deal?

Our team of life sciences advisors can help you navigate complex transactions, from early-stage licensing to full M&A.

Why This Matters